# US 2005/0239876 A1 · Tocopherol and tocotrienol aerosols

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2005/0239876 A1
- Document ID: US20050239876A1
- Status: Published application
- Kind: A1
- Application number: 11/159,917
- Filed: 2005-06-22
- Published: 2005-10-27
- Earliest claimed: 2002-11-21
- Assignees: Children's Hospital & Research Center at Oakland
- Inventors: Bruce Ames; Qing Jiang
- Web page: https://patentgrep.com/patent/US20050239876A1

## CPC

- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 31/202: having three or more double bonds, e.g. linolenic (eicosanoids, e.g. leukotrienes A61K31/557)
- A61K 31/355: Tocopherols, e.g. vitamin E
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Anti-inflammatory compositions include medicaments comprising predetermined amounts of a phytyl substituted chromanol and a prostaglandin E2 inhibitor, wherein: said medicament is in unit dosage form suitable for pharmaceutical administration; said phytyl substituted chromanol is a gamma-tocopherol, delta-tocopherol, gamma-tocotrienol or delta-tocotrienol; said PGE2 inhibitor is a non-steroidal anti-inflammatory drug or an omega-3 fatty acid, such as docosahexaenoic acid and eicosapentaenoic acid.

## Claims

### Claim at position 1

1-13. (canceled)

### Claim 14

A method of inhibiting cancer cell proliferation, the method comprising the step of treating cells with a medicament comprising a synergistic combination of gamma-tocopherol and at least one additional phytyl substituted-chromanol selected from the group consisting of delta-tocopherol, gamma-tocotrienol, and delta-tocotrienol,
wherein the medicament comprises less than 5% alpha-tocopherol, and the cancer is selected from prostate cancer and lung cancer, whereby cancer cell proliferation is inhibited.

### Claim 15 (depends on 14)

The method of claim 14 wherein the medicament comprises less than 0.5% alpha-tocopherol.

### Claim 16 (depends on 14)

The method of claim 14 wherein the medicament comprises less than 0.05% alpha-tocopherol.

### Claim 17 (depends on 14)

The method of claim 14 wherein the medicament comprises a combination of gamma-tocopherol and delta-tocopherol.

### Claim 18 (depends on 14)

The method of claim 14 wherein the medicament comprises a combination of gamma-tocopherol and gamma-tocotrienol.

### Claim 19 (depends on 14)

The method of claim 14 wherein the medicament comprises a combination of gamma-tocopherol, delta-tocopherol, and gamma-tocotrienol.

### Claim 20 (depends on 14)

The method of claim 14 wherein the medicament additionally comprises a PGE2 inhibitor selected from the group consisting of an omega-3 fatty acid cyclooxygenase substrate and a non-steroidal anti-inflammatory drug (NSAID) cyclooxygenase inhibitor.

### Claim 21 (depends on 14)

The method of claim 14 wherein the medicament additionally comprises aspirin.

### Claim 22 (depends on 14)

The method of claim 14 wherein the cells are lung epithelial cancer cells.

### Claim 23 (depends on 14)

The method of claim 14 wherein the cells are prostate epithelial cancer cells.

### Claim 24 (depends on 14)

The method of claim 14 wherein the medicament is administered to a patient orally.

### Claim 25 (depends on 14)

The method of claim 14 wherein the medicament is administered to a patient in an inhalant dosage form.

### Claim 26

A medicament in an inhalant dosage form, the medicament comprising a combination of effective and synergistic amounts of gamma-tocopherol and at least one additional phytyl substituted chromanol selected from the group consisting of delta-tocopherol, gamma-tocotrienol, and delta-tocotrienol; wherein the medicament comprises less than 5% alpha-tocopherol.

### Claim 27 (depends on 26)

The medicament of claim 26 that comprises less than 0.5% alpha-tocopherol.

### Claim 28 (depends on 26)

The medicament of claim 26 that comprises less than 0.05% alpha-tocopherol.

### Claim 29 (depends on 26)

The medicament of claim 26 that comprises a combination of gamma-tocopherol and delta-tocopherol.

### Claim 30 (depends on 26)

The medicament of claim 26 that comprises a combination of gamma-tocopherol and gamma-tocotrienol.

### Claim 31 (depends on 26)

The medicament of claim 26 that comprises a combination of gamma-tocopherol, delta-tocopherol, and gamma-tocotrienol.

### Claim 32 (depends on 26)

The medicament of claim 26 that additionally comprises a PGE2 inhibitor selected from the group consisting of an omega-3 fatty acid cyclooxygenase substrate and a non-steroidal anti-inflammatory drug (NSAID) cyclooxygenase inhibitor.

### Claim 33 (depends on 26)

The medicament of claim 26 that additionally comprises aspirin.
